Evaluation the Effect of Ticoplanin in Patients With Coronavirus Disease

Study of the Efficacy of Teicoplanin on mortality rate of patients with COVID-19 Infection: A randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161204031229N3

Enrollment

Registered

2020-04-08

Start date

2020-03-30

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Tab Hydroxychloroquine 200 mg two tablet P.O. BID for first day then 200 mg BID seven days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for seven da

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Laboratory confirmed COVID-19 with RT-PCR Laboratory confirmed COVID-19 with lung CT scan

Exclusion criteria

Exclusion criteria: Chronic kidney Disease Acute kidney injury Pregnancy Breastfeeding

Design outcomes

Primary

Measure	Time frame
Measurement of inflammatory markers (CRP). Timepoint: at baseline and discharge time. Method of measurement: ELISA.;WBC count. Timepoint: at baseline and discharge time. Method of measurement: Blood count.;Evaluation of lung CT scan. Timepoint: at baseline and discharge time. Method of measurement: Radiologic finding.;Evaluation of inflammatory marker ESR. Timepoint: at baseline and discharge time. Method of measurement: Blood count.	—

Measure

Time frame

Measurement of inflammatory markers (CRP). Timepoint: at baseline and discharge time. Method of measurement: ELISA.;WBC count. Timepoint: at baseline and discharge time. Method of measurement: Blood count.;Evaluation of lung CT scan. Timepoint: at baseline and discharge time. Method of measurement: Radiologic finding.;Evaluation of inflammatory marker ESR. Timepoint: at baseline and discharge time. Method of measurement: Blood count.

—

Secondary

Measure	Time frame
Body temperature. Timepoint: at baseline and discharge time. Method of measurement: Thermometer.;Fever. Timepoint: at baseline and discharge time. Method of measurement: Thermometer.;Respiratory rate >24/min. Timepoint: at baseline and discharge time. Method of measurement: Counting of respiratory rate in minutes.;Systolic blood pressure <90 mm Hg. Timepoint: at baseline and discharge time. Method of measurement: Manometer.;Oxygen saturation. Timepoint: at baseline and discharge time. Method of measurement: oximeter Pulse.;Pulse rate. Timepoint: at baseline and discharge time. Method of measurement: Counting of pulse rate in minutes.;Level of consciousness or new confusion. Timepoint: at baseline and discharge time. Method of measurement: With glasgow coma scale.	—

Measure

Time frame

Body temperature. Timepoint: at baseline and discharge time. Method of measurement: Thermometer.;Fever. Timepoint: at baseline and discharge time. Method of measurement: Thermometer.;Respiratory rate >24/min. Timepoint: at baseline and discharge time. Method of measurement: Counting of respiratory rate in minutes.;Systolic blood pressure <90 mm Hg. Timepoint: at baseline and discharge time. Method of measurement: Manometer.;Oxygen saturation. Timepoint: at baseline and discharge time. Method of measurement: oximeter Pulse.;Pulse rate. Timepoint: at baseline and discharge time. Method of measurement: Counting of pulse rate in minutes.;Level of consciousness or new confusion. Timepoint: at baseline and discharge time. Method of measurement: With glasgow coma scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Eshraghi

Iran University of Medical Sciences

aepharm@gmail.com+98 21 6435 2564

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026